Esperion Therapeutics Inc... (ESPR)
NASDAQ: ESPR
· Real-Time Price · USD
0.85
-0.02 (-2.37%)
At close: May 30, 2025, 3:59 PM
0.87
2.45%
After-hours: May 30, 2025, 07:57 PM EDT
-2.37% (1D)
| Bid | 0.83 |
| Market Cap | 168.29M |
| Revenue (ttm) | 259.57M |
| Net Income (ttm) | -153.22M |
| EPS (ttm) | -0.85 |
| PE Ratio (ttm) | -1 |
| Forward PE | -5.13 |
| Analyst | Buy |
| Ask | 0.88 |
| Volume | 4,255,434 |
| Avg. Volume (20D) | 5,519,945 |
| Open | 0.87 |
| Previous Close | 0.87 |
| Day's Range | 0.84 - 0.87 |
| 52-Week Range | 0.69 - 3.94 |
| Beta | 0.74 |
About ESPR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ESPR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ESPR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+12.03%
Esperion Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
5 months ago
+5.58%
Esperion Therapeutics shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced a price target of $8.
3 weeks ago · seekingalpha.com
Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call TranscriptEsperion Therapeutics, Inc. (NASDAQ:ESPR ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Ch...
2 months ago · seekingalpha.com
Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call TranscriptEsperion Therapeutics, Inc. (NASDAQ:ESPR ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and ...
